Published studies on omega 3 fatty acids in the treatment of bipolar disorder and schizophrenia have shown reductions in time to recurrence, a decrease in the positive and negative symptoms of schizophrenia, and improvements in Clinical Global Impression Scale, Young Mania Rating Scale, and HAM-D scores. The following are the hypotheses: * Omega 3 fatty acids will be superior to placebo in the acute treatment of global autism. * Omega 3 fatty acids will be superior to placebo in improving aggression and irritability associated with autism. * Omega 3 fatty acids will be superior to placebo in improving functional ability.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Clinical Global Impression Scale(CGI)- Improvement
Timeframe: Administered biweekly, endpoint score (week 12) only used for data analysis
Aberrant Behavior Checklist (ABC)
Timeframe: Administered every 4 weeks, 12 week scores used for means, score on irritability subscale reported
Vineland Adaptive Behavior Scale
Timeframe: Administered during the baseline visit and on week 12 ( termination)